Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
about
Ibritumomab tiuxetan for non-Hodgkin's lymphoma.Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma.Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of diseaseYttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma.Advances in the treatment for haematological malignancies.Follicular lymphoma: today's treatments and tomorrow's targets.Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma.Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.Diversity in antibody-based approaches to non-Hodgkin lymphoma.Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review.An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
P2860
Q33371489-D84DB268-D549-4DE9-9577-FF0CB27BBC51Q33380518-C936DA20-7194-4409-A47D-D72CCB268300Q33397845-BC4EB007-1B35-4757-B264-D374CB9C11C2Q33870879-D1468809-8008-4ADA-9BF9-6BAA341F5E05Q36074023-46AC53C7-DBCE-40D1-8B4F-8F2D8B55EE8DQ36429723-816F3C77-8329-4AAF-A269-B24FBDF9EF57Q36521854-94B415B4-4703-447A-B6B6-7E86DD4645C7Q36964464-67BCB0BB-9525-4069-82A8-6F8BF89ECC2AQ37676785-5D325035-81BD-4E15-B575-03439290FA9DQ37785097-80C671DB-4C47-404B-8712-9388AFB923B2Q38902248-AA63733F-FA1C-4DC7-A348-05A02B73BB23Q41760763-B96EF4CA-04E8-4F2F-AAD9-6AA28CDED25B
P2860
Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Report of a European consensus ...... iuxetan (Zevalin) in lymphoma.
@ast
Report of a European consensus ...... iuxetan (Zevalin) in lymphoma.
@en
type
label
Report of a European consensus ...... iuxetan (Zevalin) in lymphoma.
@ast
Report of a European consensus ...... iuxetan (Zevalin) in lymphoma.
@en
prefLabel
Report of a European consensus ...... iuxetan (Zevalin) in lymphoma.
@ast
Report of a European consensus ...... iuxetan (Zevalin) in lymphoma.
@en
P356
P1433
P1476
Report of a European consensus ...... tiuxetan (Zevalin) in lymphoma
@en
P2093
A Hagenbeek
P304
P356
10.1093/ANNONC/MDI148
P577
2005-03-31T00:00:00Z